MedTrace Logo

Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension

NCT06518850 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-07-24

No results posted yet for this study

Summary

Most studies of bloating have focused on functional factors, while data on organic abdominal distention are rare, and studies that combine small intestine bacterial overgrowth and/or oral cecum transit time abnormalities are more urgent to explore. On this basis, patients with functional abdominal distension complicated with small intestine bacterial overgrowth were divided according to whether there was abnormal oral cecum transit time, and given the same treatment plan. The relief effect of abdominal distension, small intestine bacterial overgrowth turning negative and oral cecum transit time recovery were observed, so as to further clarify the cause of abdominal distension patients.

Conditions

  • Small Intestine Bacterial Overgrowth

Interventions

DRUG

Rifaximin

Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.

Sponsors & Collaborators

  • Navy General Hospital, Beijing

    collaborator OTHER

  • Air Force Military Medical University, China

    collaborator OTHER

  • Beijing Tongren Hospital

    collaborator OTHER

  • Beijing Friendship Hospital

    collaborator OTHER

  • Beijing Chao Yang Hospital

    collaborator OTHER

  • Beijing Tiantan Hospital

    collaborator OTHER

  • The Luhe Teaching Hospital of the Capital Medical University

    collaborator OTHER

  • China-Japan Friendship Hospital

    collaborator OTHER

  • Beijing Aerospace General Hospital

    collaborator OTHER

  • Beijing Jishuitan Hospital

    collaborator OTHER

  • Peking University Third Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Jing-Nan Li, MD,Ph.D · Peking Union Medical College Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2024-12-31
Completion
2025-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06518850 on ClinicalTrials.gov